

## Special Issue

# Functional Biomarkers for Cardiometabolic Disorders

### Message from the Guest Editor

Cardiometabolic disorders are a set of maladaptive cardiovascular, renal, thrombotic, inflammatory, and metabolic diseases, long been recognized by worldwide health organizations. Cardiometabolic disorders are the leading cause of mortality globally. Identifying novel and early-stage biomarkers of cardiovascular disorders is critical for predicting and avoiding the considerable morbidity and mortality associated with these diseases. The number of possible biomarkers that allow for the improved functional characterization of individuals with cardiometabolic disorders is constantly expanding. New biomarkers for cardiovascular and metabolic disease characterization are being developed by combining continuous physiological signal detection with various analytic approaches. Functional biomarkers can be derived from wearable devices or sequential measures with point-of-care devices to boost early disease detection, disease status surveillance, and therapy efficacy. Furthermore, systems biology approaches have the potential to identify biomarkers for diagnostic, prognostic, or predictive purposes.

### Guest Editor

Prof. Dr. Ovidiu Constantin Baltatu

Center of Innovation, Technology and Education (CITE) at Anhembi Morumbi University—Anima Institute, Sao Jose dos Campos, Brazil

### Deadline for manuscript submissions

closed (30 November 2023)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/157640](https://mdpi.com/si/157640)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).